Corvus Pharmaceuticals, Inc. Payments to Acquire Debt Securities, Available-for-sale
Corvus Pharmaceuticals, Inc. (CRVS) reported Payments to Acquire Debt Securities, Available-for-sale of $209.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $47.74M, a 20.94% increase year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $161.74M, a 1998.30% increase year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $13.42M, a 34.10% decline year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $31.15M, a 65.37% increase year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $91.75M, a 30.85% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $70.12M, a 49.04% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $47.05M, a 28.92% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $66.19M, a 607.40% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $209.48M 10-Q · filed 2026-08-06 | $222.90M derived: sum of 3 quarters · filed 2026-08-06 | $254.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $161.74M 10-Q · filed 2026-05-07 | $175.16M derived: sum of 2 quarters · filed 2026-05-07 | $206.30M derived: sum of 3 quarters · filed 2026-05-07 | $245.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $13.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $44.57M derived: sum of 2 quarters · filed 2026-03-12 | $84.04M derived: sum of 3 quarters · filed 2026-08-06 | $91.75M 10-K · filed 2026-03-12 |
| 2025-09-30 | $31.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $70.62M derived: sum of 2 quarters · filed 2026-08-06 | $78.33M 10-Q · filed 2025-11-04 | $98.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $39.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $47.18M 10-Q · filed 2026-08-06 | $67.54M derived: sum of 3 quarters · filed 2026-08-06 | $86.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.71M 10-Q · filed 2026-05-07 | $28.07M derived: sum of 2 quarters · filed 2026-05-07 | $46.91M derived: sum of 3 quarters · filed 2026-05-07 | $73.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $39.20M derived: sum of 2 quarters · filed 2026-03-12 | $65.49M derived: sum of 3 quarters · filed 2026-03-12 | $70.12M 10-K · filed 2026-03-12 |
| 2024-09-30 | $18.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $45.13M derived: sum of 2 quarters · filed 2025-11-04 | $49.76M 10-Q · filed 2025-11-04 | $61.18M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $26.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $30.92M 10-Q · filed 2025-08-07 | $42.35M derived: sum of 3 quarters · filed 2026-03-12 | $44.16M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $4.63M 10-Q · filed 2025-05-08 | $16.05M derived: sum of 2 quarters · filed 2026-03-12 | $17.87M derived: sum of 3 quarters · filed 2026-03-12 | $38.59M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $11.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $13.24M derived: sum of 2 quarters · filed 2026-03-12 | $33.96M derived: sum of 3 quarters · filed 2026-03-12 | $47.05M 10-K · filed 2026-03-12 |
| 2023-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $22.53M derived: sum of 2 quarters · filed 2024-11-12 | $35.62M 10-Q · filed 2024-11-12 | $54.92M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | $20.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $33.81M 10-Q · filed 2024-08-06 | $53.11M derived: sum of 3 quarters · filed 2025-03-25 | $70.58M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | $13.09M 10-Q · filed 2024-05-07 | $32.39M derived: sum of 2 quarters · filed 2025-03-25 | $49.86M derived: sum of 3 quarters · filed 2025-03-25 | $52.90M derived: sum of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | $19.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $36.77M derived: sum of 2 quarters · filed 2025-03-25 | $39.81M derived: sum of 3 quarters · filed 2025-03-25 | $66.19M 10-K · filed 2025-03-25 |
| 2022-09-30 | $17.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $20.51M derived: sum of 2 quarters · filed 2023-11-07 | $46.89M 10-Q · filed 2023-11-07 | $51.38M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $29.42M 10-Q · filed 2023-08-08 | $33.91M derived: sum of 3 quarters · filed 2024-03-19 | $34.07M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $26.38M 10-Q · filed 2023-05-08 | $30.88M derived: sum of 2 quarters · filed 2024-03-19 | $31.03M derived: sum of 3 quarters · filed 2024-03-19 | $32.42M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.65M derived: sum of 2 quarters · filed 2024-03-19 | $6.04M derived: sum of 3 quarters · filed 2024-03-19 | $9.36M 10-K · filed 2024-03-19 |
| 2021-09-30 | $154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.54M derived: sum of 2 quarters · filed 2022-11-03 | $4.86M 10-Q · filed 2022-11-03 | $11.94M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $4.71M 10-Q · filed 2022-08-08 | $11.79M derived: sum of 3 quarters · filed 2023-03-28 | $17.52M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $3.32M 10-Q · filed 2022-05-05 | $10.40M derived: sum of 2 quarters · filed 2023-03-28 | $16.13M derived: sum of 3 quarters · filed 2023-03-28 | $34.45M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $12.81M derived: sum of 2 quarters · filed 2023-03-28 | $31.13M derived: sum of 3 quarters · filed 2023-03-28 | $42.54M 10-K · filed 2023-03-28 |
| 2020-09-30 | $5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $24.05M derived: sum of 2 quarters · filed 2021-11-01 | $35.46M 10-Q · filed 2021-11-01 | $59.18M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $18.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $29.73M 10-Q · filed 2021-08-02 | $53.45M derived: sum of 3 quarters · filed 2022-03-10 | $103.82M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $11.41M 10-Q · filed 2021-04-29 | $35.12M derived: sum of 2 quarters · filed 2022-03-10 | $85.50M derived: sum of 3 quarters · filed 2022-03-10 | $120.09M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $23.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $74.08M derived: sum of 2 quarters · filed 2022-03-10 | $108.68M derived: sum of 3 quarters · filed 2022-03-10 | $138.59M 10-K · filed 2022-03-10 |
| 2019-09-30 | $50.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $84.97M derived: sum of 2 quarters · filed 2020-10-29 | $114.87M 10-Q · filed 2020-10-29 | $146.93M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $34.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $64.50M 10-Q · filed 2020-07-30 | $96.56M derived: sum of 3 quarters · filed 2021-03-25 | $126.91M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $29.90M 10-Q · filed 2020-04-30 | $61.96M derived: sum of 2 quarters · filed 2021-03-25 | $92.31M derived: sum of 3 quarters · filed 2021-03-25 | $175.97M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $32.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $62.41M derived: sum of 2 quarters · filed 2021-03-25 | $146.06M derived: sum of 3 quarters · filed 2021-03-25 | $161.86M 10-K · filed 2021-03-25 |
| 2018-09-30 | $30.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $114.01M derived: sum of 2 quarters · filed 2019-10-29 | $129.81M 10-Q · filed 2019-10-29 | $143.04M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | $83.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $99.45M 10-Q · filed 2019-08-01 | $112.69M derived: sum of 3 quarters · filed 2020-03-09 | $140.69M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | $15.80M 10-Q · filed 2019-05-09 | $29.03M derived: sum of 2 quarters · filed 2020-03-09 | $57.03M derived: sum of 3 quarters · filed 2020-03-09 | $86.09M derived: sum of 4 quarters · filed 2020-03-09 |
| 2017-12-31 | $13.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $41.24M derived: sum of 2 quarters · filed 2020-03-09 | $70.30M derived: sum of 3 quarters · filed 2020-03-09 | $88.31M 10-K · filed 2020-03-09 |
| 2017-09-30 | $28.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $57.06M derived: sum of 2 quarters · filed 2018-11-01 | $75.07M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $29.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $47.07M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $18.01M 10-Q · filed 2018-05-03 | |||
| 2016-12-31 | $258.28M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |